CD8A and neoplasm: We applied the same partitioning analysis by using the 3-year DFS rate as the response endpoint for patient age, tumour stage, tumour site (Right vs Left CRC), KRAS mutational status and Normal Mucosa mIS (CD3/CD8 mRNA cluster-variable vs cluster-high) as input factors in 126 patients for whom all data were available from normal mucosa samples.